Altered cytokine and acute phase response protein levels in the blood of children with Downs syndrome: Relationship with dementia of Alzheimer's type

International Journal of Immunopathology and Pharmacology

Volumn 18, Issue 1, 2005, Pages 165-172

  Licastro, Federico ^a,d   Chiappelli, M ^a   Ruscica, M ^b   Carnelli, V ^c   Corsi, M M ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Dipartimento di Patologia Sperimentale   (Italy)

Author keywords

Alzheimer's disease; CRP; Down's syndrome; IL 6; IL 6R; Neopterin; Plasma levels; sICAM; sVCAM

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NEOPTERIN; VASCULAR CELL ADHESION MOLECULE 1;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; NERVE DEGENERATION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT;

EID: 14844327741     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200501800117     Document Type: Article

References (42)

1. Sever J.L., M.R. Gilkeson, T.C. Chen, A.C. Ley and D. Edmonds. 1970. Epidemiology of mongolism in the Collaborative Project. Ann. N.Y. Acad. Sci. 171:328.
2. Baird P.A. and A.D. Sadovnick. 1988. Causes of death to age 30 in Down syndrome. Am. J. Hum. Genet. 43: 239.
3. Franceschi C., F. Licastro, M. Chiricolo, et al. 1981. Deficiency of autologous mixed lymphocyte reactions and thymic factor level in Down syndrome. J. Immunol. 126:2161.
4. Wisniewski K., H.M. Wisniewski and G.Y. Wen. 1985. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17:278.
5. Mann D.M. and M.M. Esiri. 1989. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J. Neurol. Sci. 89:169.
6. Mrak R.E., J.G. Sheng and S.T. Griffin. 1995. Glial cytokines in Alzheimer's disease: review and pathogenetic implications. Human Pathol. 26:816.
7. Licastro F., M. Mallory, L.A. Hansen and E. Masliah. 1998. Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J. Neuroimmunol. 88:105.
8. Licastro F. and M. Chiappelli. 2003. Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background. Mech. Ageing Develop. 124:539.
9. rd White and C. Araoz. 1989. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down's syndrome and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 86:7611.
10. Sheng J.C., W.S. Griffin, M.C. Royston and R.E. Mrak. 1998. Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implication for neuritic plaque formation in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 24:278.
11. Bauer J., S. Strauss, U. Schreiter-Gasser, U. Ganter, P. Schlegel, I. Witt, B. Yolk and M. Berger. 1991. Interleukin-6 and α-2-macroglobulin indicate an acute phase state in Alzheimer's disease cortex. FEBS Lett. 285:111.
12. Strauss S., J. Bauer, U. Ganter, U. Jonas, M. Berger and B. Volk. 1992. Detection of interleukin-6 and α-2-macroglobulin immunoreactivity in cortex and hyppocampus of Alzheimer's disease patients. Lab. Invest. 66:223.
13. Huell M., S. Strauss, B. Volk, M. Berger and J. Bauer. 1995. Interleukin-6 is present in early stages of plaque formation and is restricted to the brain of Alzheimer's disease patients. Acta Neuropathol. 89:544.
14. Webster S., L.F. Lue, L. Brachova, et al. 1997. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Ageing 18:415.
15. McGeer P.L. and E.G. McGeer. 2002. The possible role of complement activation in Alzheimer's disease. Trends Mol. Med. 8:519.
16. Head E., B.Y. Azizeh, I.T. Lott, A.J. Tenner, C.W. Cotman and D.H. Cribbs. 2001. Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down Syndrome. Neurobiol. Dis. 8:252.
17. Griffin W.S., Sheng J.G., M.C. Royston, et al. 1998. Glial-neuronal interactions in Alzheimer's disease: the potential role of a "cytokine cycle" in disease progression. Brain Pathol. 818:65.
18. McGeer E.G. and P.L. McGeer. 1998. The importance of inflammatory mechanisms in Alzheimer's disease. Exp. Gerontol. 33:371.
19. Licastro F. 2001. Genetic background of inflammatory molecules affects protein expression, the risk of developing Alzheimer's disease and cognitive decline. Arch. Gerontol. Geriatr. 33:227.
20. Alvarez X.A., A. Franco, F. Fernandez-Novoa and R. Cacabelos. 1996. Blood levels of histamine, IL-1 beta and TNF-alpha in patients with mild to moderate Alzheimer's disease. Mol. Chem. Neuropathol. 29:237.
21. Kalman J., A. Juhasz, G. Laird, et al. 1997. Serum interrleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease. Acta Neurol. Scand. 96:236.
22. Singh V.K. and P. Guthikonda. 1997. Circulating cytokines in Alzheimer's disease. J. Psychiatr. Res. 31:657.
23. Bonaccorso S., A. Lin, C. Song, et al. 1998. Serotonine-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT. Ageing 10:316.
24. Licastro F., S. Pedrini, L. Caputo, et al. 2000. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signal from the brain?. J. Neuroimmunol. 103:97.
25. Van Duijn C.M., A. Hofman and L. Nagelkerken. 1990. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci. Lett. 108:350.
26. Angelis P., S. Scharf, A. Mander, F. Vajda and N. Christophidis. 1998. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. Neuroscience Letters 244:106.
27. Furby A., D. Leys, A. Delacourte, L. Buee, G. Soetaert and H. Petit. 1991. Are alpha-1-antichymotrypsin and inter-alpha-trypsin inhibitor peripheral markers of Alzheimer's disease? J. Neurol. Neurosurg. Psychiatry 54:469.
28. Kuiper M.A., G.J. van-Kamp, P.L. Bergmans, P. Scheltens and E.C. Wolters. 1993. Serum alpha-1-antichymotrypsin is not a useful marker for Alzheimer's disease or dementia in Parkinson's disease. J. Neural Transm. 6:145.
29. Pirtilla T., P.D. Metha, H. Frey and H.M. Wisniewski. 1994. Alpha-1-antichymotrypsin and IL-1beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol. Aging 15:313.
30. Licastro F., M. Chiricolo, E. Mocchegiani, et al. 1994. Oral zinc supplementation in Down's syndrome subjects decreased infections and normalized some humoral and cellular immune parameters. J. Intellect. Disabil. Res. 38:149.
31. Licastro F., R.A. Mariani, G. Faldella, et al. 2001. Immune-endocrine status and coeliac disease in children with Down's syndrome: Relationships with zinc and cognitive efficiency. Brain Res. Bull. 55:313.
32. Carta M.G., P. Serra, A. Ghiani, et al. 2002. Chemokines and Pro-inflammatory Cytokines in Down's Syndrome: AN Early Marker for Alzheimer-Type Dementia? Psychother. Psychosom. 71:233.
33. McKhann G., D. Drachmen, M. Folstein, R. Katzman, D. Price and E.M. Stadlan. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer's Disease. Neurol. 34:939.
34. Ershler W.B. 1993. Interleukin-6: a cytokine for gerontologist. J. Am. Geriatric. Soc. 41:176.
35. Van Snick J. 1990. Interleukin-6: an overview. Annu. Rev. Immunol. 8:253.
36. Mohamed-Ali V., J.H. Pinkney and S.W. Coppack. 1998. Adipose tissue as an endocrine and paracrine organ. Int. J. Obesity 22:1145.
37. Peters M., K.H. Meyer zum Buschenfelde and S. Rose-John. 1996. The function of the soluble IL-6 receptor in vivo. Immunol. Lett. 54:177.
38. Ershler W.B. and E.T. Keller. 2000. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu. Rev. Med. 51:245.
39. Licastro F., L.M.E. Grimaldi, M. Bonafè, et al. 2003. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol. Aging 24:921.
40. Teller J.K., C. Russo, L.M. De Busk, et al. 1996. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nature Med. 2:93.
41. Andresen T.K., J.L. Svennevig and V. Videm. 2002. Soluble VCAM-1 is a very early marker of endothelial cell activation in cardiopulmonary bypass. Perfusion 17:15.
42. Fuchs D., G. Weiss and H. Wachter. 1993. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int. Arch. Allergy Immunol. 101:1.